Table 11 LCL maximum marginal willingness-to-pay (WTP) estimates
From: A choice experiment assessment of stated early response to COVID-19 vaccines in the USA
Variable | Class 1 | Class 2 | Class 3 |
|---|---|---|---|
Effectiveness [%] | Â | $2.94 | $8.55 |
Protection [months] | Â | $7.96 | $19.94 |
Incubation [days] | Â | -$2.35 | -$1.40 |
Severe side effects [out of 106] | Â | -$0.72 | -$1.76 |
Mild side effects [out of 10] | Â | -$10.32 | -$37.88 |
Introduced [months] | Â | $6.27 | $44.02 |
Origin (base: Germany) | Â | Â | Â |
USA | Â | $85.23 | $255.54 |
UK | Â | $31.58 | $302.38 |
China | Â | -$91.47 | Â |
Recommends (base: PCP) | Â | Â | Â |
Media | Â | -$99.04 | -$498.64 |
CDC | Â | Â | -$166.16 |
WHO | Â | -$21.10 | -$254.15 |